Novo Nordisk Q3 2026 Results: Wegovy Pill Sales Hit DKK 5.4 Billion as Company Raises Full-Year Outlook
Novo Nordisk Q3 2026 results show Wegovy pill sales of DKK 5,394 million, adjusted operating profit up 27% at constant exchange rates, and a raised 2026 outlook. The report also covers CagriSema data, DKK 8.7 billion of impairments and a CFO change.
Pfizer Q3 2026 Results: Pfizer Raises 2026 Guidance to $62–64 Billion as Launched Products Grow 32%
Pfizer Q3 2026 Results show $16.6 billion in revenue, 32% operational growth from launched and acquired products, and a raised 2026 outlook of $62.0–$64.0 billion. Pfizer also named Cecile Guegan as CFO and reported progress for Elrexfio, Litfulo, Talzenna and Tukysa.
Merck KGaA CDMO Divestment: Lonza to Acquire Life Science CDMO Business for Mid-Triple-Digit Million Euros
Merck KGaA has signed a definitive agreement to divest its CDMO business to Lonza for a mid-triple-digit million-euro amount. The deal covers five US-based operations and is expected to close in mid-2027.
AstraZeneca Q3 2026 Results: Total Revenue Rises 7% to $46.9bn as Oncology Leads Growth and FY2026 Guidance Holds
AstraZeneca Q3 2026 results, published 30 October 2026, show nine-month revenue of $46.9bn, up 7% at CER, and Core EPS of $8.00, up 14%. Oncology led growth, the company reconfirmed FY2026 guidance, and it reported 12 positive Phase III programme readouts.
AbbVie Q3 2026 Results: Skyrizi, Rinvoq and Vraylar Drive $17.404 Billion Revenue as EPS Guidance Rises
AbbVie Q3 2026 Results show $17.404B revenue, led by Skyrizi and Rinvoq, with higher 2026 EPS guidance and a 5.2% dividend increase.
Merck Daejeon Bioprocessing Center Opens With €300 Million Investment to Expand Asia-Pacific Biologics Supply
The Merck Daejeon bioprocessing center opened on 29 October 2026 with a €300 million-plus investment, adding cell culture media, process liquids and sterile sampling capacity for Asia-Pacific biopharma manufacturers.
Sandoz 2026 Sales Rise 5% at CC as Biosimilars Climb 19%; Core-EBITDA Margin Guidance Upgraded to 23.0-23.5%
Sandoz 2026 sales reached USD 8,703 million in the first nine months, up 5% at constant currencies, with biosimilars up 19% and generics down 1%. The company narrowed full-year net-sales growth guidance to 5-6% and upgraded its core-EBITDA margin outlook to 23.0-23.5%.
Novartis Q3 2026 Results: Kisqali and Kesimpta Lift Sales as Novartis Raises Full-Year Core Operating Income Guidance
Novartis Q3 2026 results show net sales of USD 14.5 billion (+4%) and core operating income up 11%. The company raised its full-year core operating income guidance despite a USD 1.9 billion del-desiran impairment.
IQVIA Q3 2026 Results: IQVIA Holdings Reports $4,428 Million Revenue and Raises Full-Year 2026 Guidance
IQVIA Q3 2026 Results show revenue of $4,428 million, adjusted diluted EPS of $3.34, $3.2 billion in R&D Solutions net new bookings and raised full-year 2026 guidance.
Pfizer TALZENNA XTANDI Approval: FDA Clears Combination for an Earlier Metastatic Prostate Cancer Setting
The FDA has expanded the TALZENNA XTANDI approval to men with HRR gene-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. The decision rests on Phase 3 TALAPRO-3 data showing an estimated 52% reduction in the risk of radiographic progression or death.